Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Dose limiting toxicity

Outcome Time Frame:

Cycle 1

Safety Issue:

Yes

Principal Investigator

MD

Investigator Role:

Study Director

Investigator Affiliation:

Amgen

Authority:

United States: Food and Drug Administration

Study ID:

20030116

NCT ID:

NCT00093873

Start Date:

July 2003

Completion Date:

December 2006

Related Keywords:

• Tumors
• Cancer
• antiangiogenesis
• Solid Tumors

Name	Location